BMC Cancer 2006, 6:132 Table 1: Oligonucleotides and plasmids used in this study. PCR products/Plasmids 1163 bp 1374 bp 1926 bp 2158 bp 2299 bp 2628 bp 2881 bp 3588 bp 4709 bp 4970 bp ATGc ATGm NFY-868 Ebox-952 139 bp (MSP)2 142 bp (MSP)2 pCR1163 pCR1374 pCR2158 pCR2299 pCR2628 pCR2881 pCR4.7A1b pCR4970 pFPGS-cDNA pGL1163-2628 pGL1374 pGL2158-2628 pGL2256 pGL2299-2628 pGL2628 pGL2628-ATGc pGL2628-ATG pGL2628-ATGm/c pGL2881-2628 pGL3588-2628 pGL4689 pGL868NFY-ATGm/c pGL952NFY-ATGm/c http://www.biomedcentral.com/1471-2407/6/132 Forward and Reverse primers/Description exon15-53F (5'-CGTTCTCCCCATGAACTTACA) exon15-1215R (5'-AGGGTCTAGGCTGCAAGAAAG) intron0F-141 (5'-ACCCCAGCAGTGTGTGAAGAG) intron1R-6537 (5'-CCCACCCCCAGATCAATACTC) 1exonF (5'-GGGGGCGCCGGGACTATGTCG) 15exonR-c1934 (5'-TCTCCCGGCCTCCCATCCCAA) 46714F (5'-AGAAGTTCTGGTGGGAAGGAA) 48871R (5'-CAGACCCTGGACTAGATGCTG) 48538F (5'-TAAGTGGGGGATGAGTCCAG) 50836R (5'-CCCAGATTCCAGCATCCTAA) 17595F (5'-GGCGCAGAGGCTAAGAATAAG) 20202R2 (5'-CCCCCAGCCTCCAGGATGTTC) exon15-53F (5'-CGTTCTCCCCATGAACTTACA) exon15-2933R (5'-CCACACAGGAGTCAGGAATGT) F8256K (5'-GAGAGAGGTACCCCCGTGACTCCTGGTGGCTGC) R11843K (5'-AATTCGGTACCCCTGGTCACCGGGTTCTCCTA) UA1F1979 (5'-CGCACACACCGCCAACTGTTC) UA1R6667 (5'-CCTGGTCACCGGGTTCTCCTA) UAP-15639 (5'-GAGTGGCCCTTATGTACCGAC) 1R-20591 (5'-GGGCAACCGGCTCTTGAC) QC20060F (5'-CGCAGGAGCCGAGCTCGGAGTACCAGGTAT) QC20060R (5'-ATACCTGGTACTCCGAGCTCGGCTCCTGCG) QC19934F (5'-GCGCCGGGACTAGTTCGCGGGCGCGG) QC19934R (5'-CCGCGCCCGCGAACTAGTCCCGGCGC) NFY-868F (5'-GACGCTGCGCTGAAAAGCTGGGGGCGGGGC) NFY-868R (5'-GCCCCGCCCCCAGCTTTTCAGCGCAGCGTC) E47-952F (5'-GGGCGCGGAGCCATTCGCGCGCCGCTCTATTC) E47-952R (5'GAATAGAGCGGCGCGCGAATGGCTCCGCGCCC) M19571F 5'-GTAGAGATTGAGGGTTGTTGATTC M19709R 5'-CGAAACCAAATTTATAAATATACGCT U19571F 5'-GTAGAGATTGAGGGTTGTTGATTT U19712R 5'-CCTCAAAACCAAATTTATAAATATCACT 1163 bp PCR fragment from NALM6 cloned into pCR2.1 TOPO 1374 bp PCR fragment from BM cloned into pCR2.1-TOPO 2158 bp PCR fragment from NALM6 cloned into pCR2.1-TOPO 2299 bp PCR fragment from NALM6 cloned into pCR2.1-TOPO 2628 bp PCR fragment from BAC RCPI-11 cloned into pCR2.1-TOPO 2881 bp PCR fragment from NALM6 cloned into pCR2.1-TOPO 4709 bp PCR fragment from BM cloned in pCR2.1-TOPO 4970 bp PCR fragment from BAC RCPI-11 cloned into pCR2.1-TOPO 1926 bp PCR from NALM6 cloned into pCR2.1-TOPO 1163 bp Acc65I fragment PCR from pCR1163 cloned in pGL2628ATGm/ c 1374 bp HindIII PCR fragment from pCR1374 cloned into pGL3 2158 bp Acc65I PCR fragment from pCR2158 cloned in pGL2628ATGm/ c 2316 bp HindIII fragment from pCR4.7-A1b cloned into pGL3 2299 bp Acc65I PCR fragment from pCR2299 cloned in pGL2628ATGm/ c 2628 bp SacI-EcoRV fragment from pCR2628 cloned into pGL3 cytosolic ATG mutagenized to TCG (ATGc) in pGL2628 mitochondrial ATG mutagenized to AGT (ATGm) in pGL2628 cytosolic ATG mutagenized to TCG (ATGc) in pGL2628-ATGm 2881 bp Acc65I PCR fragment from pCR2881 cloned in pGL2628ATGm/ c 3588 bp Acc65I PCR fragment from pCR4.7A1b in pGL2628ATGm/c 4708 bp EcoRV-BamHI fragment from pCR4970 cloned into pGL3 NFY-868 mutation in pGL2628-ATGm/c Ebox-952 mutation in pGL2628-ATGm/c 1Nucleotides substituted are in bold italic. 2 MSP, Methyl-Specific PCR BM, normal human bone marrow genomic DNA. To construct pGL1163-2628, pGL2158-2628, pGL2299-2628, pGL2881-2628, and pGL3588-2628, a sequence (5'-AATTCGGTACC) containing the Acc65I restriction site (underlined) was added to the 5'-end of the oligonucleotide primers used for the PCR amplification. Page 3 of 12 (page number not for citation purposes)